UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of March 2026
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and
333-265866.
The following exhibit is attached:
| 99.1 |
|
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 4, 2026 |
KAMADA LTD. |
| |
|
| |
By: |
/s/ Nir Livneh |
| |
|
Nir Livneh
Vice President, General Counsel and
Corporate Secretary |
EXHIBIT INDEX
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1 |
|
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 |
Exhibit 99.1
Kamada to Announce Fiscal Year and Fourth
Quarter 2025 Financial Results on March 11, 2026
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, NJ – March
4, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated
for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results
for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March
11, 2026.
Kamada’s management will host an investment
community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and
other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or
1-201-689-8263 (International) using conference I.D. 13758519. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1751343&tp_key=e8c73d1516.
About Kamada
Kamada Ltd. (the “Company”) is a global
biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling
shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving
profitable growth through four primary growth pillars: First, organic growth of its specialty plasma therapies products portfolio, including
continued investment in the commercialization and life cycle management of its proprietary products, including six FDA-approved specialty
plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®,
and two types of equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel &
MENA through in-licensing partnerships, mainly through the launch of several biosimilar products in Israel. Third, the Company is expanding
its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers,
and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in
the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions,
business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products
portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company
is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product
candidates, targeting areas of significant unmet medical need.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
